TXNL1 Antibody

What is TXNL1 and why is it important to study?

TXNL1 (Thioredoxin-like protein 1), also known as TRP32, TXL, or TXNL, is a 32.3 kDa protein belonging to the thioredoxin family. It has a distinctive structure with two domains: an N-terminal domain that shares 43% identity with human thioredoxin (TXN) and a unique C-terminal domain. TXNL1 is significant because of its dual functionality in cellular processes - it acts both as a redox-active thioredoxin-like protein involved in disulfide reduction reactions and as an ATP-independent molecular chaperone. It's also involved in cellular responses to sugar starvation stress and functions as an effector of oxidants or redox sensor that couples oxidative stress to endocytosis by converting redox changes into a specific GDI:Rab5-mediated endocytic response . The ubiquitous expression of TXNL1 across tissues and its conservation from yeast to mammals suggest fundamental biological importance, making it a valuable target for research into redox homeostasis, protein quality control, and cellular stress responses.

What are the key applications of TXNL1 antibodies in research?

TXNL1 antibodies are versatile research tools with several validated applications:

These applications enable researchers to study TXNL1 expression patterns, subcellular localization, interaction partners, and functional roles in various physiological and pathological contexts.

How do I select the appropriate TXNL1 antibody for my experiment?

Selecting the right TXNL1 antibody depends on several experimental considerations:

• Target species reactivity: Verify that the antibody recognizes TXNL1 in your species of interest. Most commercial antibodies react with human, mouse, and rat TXNL1, but cross-reactivity varies between products .

• Application compatibility: Ensure the antibody is validated for your specific application (WB, IHC, IF, IP). Some antibodies perform well in multiple applications while others are optimized for specific techniques .

• Epitope recognition: Consider which region of TXNL1 the antibody recognizes. Antibodies targeting different epitopes may reveal different aspects of TXNL1 biology, especially if studying specific domains (N-terminal thioredoxin domain vs. C-terminal domain).

• Validation data: Review published literature and manufacturer validation data for evidence of specificity and performance in conditions similar to your experimental system .

• Format needs: Determine if you need unconjugated antibodies or those conjugated to specific tags (e.g., fluorophores, enzymes) based on your detection method.

For rigorous research, validating antibody specificity in your experimental system using appropriate controls (such as TXNL1 knockdown/knockout samples) is highly recommended.

What are the optimal conditions for detecting TXNL1 using Western blotting?

For optimal detection of TXNL1 via Western blotting, consider the following protocol refinements:

• Sample preparation:

  • Lyse cells in RIPA buffer supplemented with protease inhibitors

  • Include reducing agents (β-mercaptoethanol or DTT) in sample buffer to maintain TXNL1's redox state

  • Heat samples at 95°C for 5 minutes before loading

• Gel electrophoresis and transfer:

  • Use 10-12% polyacrylamide gels for optimal resolution of the 32 kDa TXNL1 protein

  • Transfer to PVDF membranes at 100V for 60-90 minutes or 30V overnight at 4°C

• Antibody conditions:

  • Block with 5% non-fat milk or BSA in TBST

  • Incubate with primary TXNL1 antibody at recommended dilutions (1:500-1:2000)

  • For cell line detection, K-562 and HL-60 cells have shown reliable TXNL1 expression

• Detection optimization:

  • Use enhanced chemiluminescence (ECL) or fluorescence-based detection systems

  • Expect to observe bands at approximately 32 kDa, which corresponds to the predicted molecular weight of TXNL1

• Controls:

  • Include positive control samples (K-562 or HL-60 cell lysates)

  • Consider using TXNL1 knockdown/knockout samples as negative controls

TXNL1 typically appears as a distinct band at 32 kDa, consistent with its calculated molecular weight. Multiple bands may indicate post-translational modifications, degradation products, or antibody cross-reactivity that should be carefully evaluated.

How can I optimize immunohistochemical detection of TXNL1 in tissue samples?

Successful immunohistochemical detection of TXNL1 requires attention to several critical parameters:

• Tissue fixation and processing:

  • Use 10% neutral buffered formalin for fixation (6-24 hours depending on tissue thickness)

  • Paraffin embedding and 4-6 μm sectioning provide optimal morphology preservation

• Antigen retrieval:

  • TXNL1 detection typically requires heat-induced epitope retrieval

  • Recommended: TE buffer at pH 9.0 (primary option) or citrate buffer at pH 6.0 (alternative)

  • Heat to 95-98°C for 15-20 minutes in a pressure cooker or water bath

• Blocking and antibody incubation:

  • Block with 5-10% normal serum from the species of secondary antibody origin

  • Use TXNL1 antibody at 1:100-1:400 dilution

  • Incubate at 4°C overnight for best results

• Detection systems:

  • Polymer-based detection systems offer higher sensitivity with lower background

  • DAB (3,3'-diaminobenzidine) provides a stable brown precipitate for visualization

• Counterstaining and controls:

  • Light hematoxylin counterstaining helps visualize tissue architecture

  • Include human heart or thyroid cancer tissue as positive controls

  • Use isotype-matched IgG as negative control

• Interpretation guidelines:

  • TXNL1 typically exhibits cytoplasmic staining pattern

  • Evaluate staining intensity and distribution pattern

  • Consider cell-type specific expression patterns when analyzing results

Titration of antibody concentration is essential as optimal dilutions may vary between tissue types and experimental systems.

What are the specific considerations when studying TXNL1's dual functions in redox reactions and chaperone activity?

Investigating TXNL1's dual functionality requires specialized experimental approaches to distinguish between its redox and chaperone activities:

• Redox activity assessment:

  • Insulin disulfide reduction assay: Monitor reduction of insulin disulfides by TXNL1 coupled to thioredoxin reductase (TXNRD1) using NADPH as electron donor

  • DTNB (5,5'-dithiobis-(2-nitrobenzoic acid)) reduction assay: Measures TXNL1's ability to reduce disulfide bonds

  • Comparative analysis: Include thioredoxin (TXN, Trx1) as a reference to quantify TXNL1's relative redox efficacy

• Chaperone activity evaluation:

  • Protein aggregation prevention assays: Measure TXNL1's ability to prevent aggregation of proteins during thermal stress

  • Insulin solubility assay: Unlike Trx1, TXNL1 forms non-covalent complexes with reduced insulin, preventing its precipitation

  • Whole cell lysate protection: Monitor TXNL1's capacity to prevent protein aggregation during heating

• Distinguishing between functions:

  • Use Cys-to-Ser TXNL1 variants to separate redox-dependent and redox-independent activities

  • Test chaperone function in the absence and presence of TXNRD1/NADPH systems

  • Analyze protein-protein interactions using immunoprecipitation with TXNL1 antibodies under different redox conditions

• Methodological controls:

  • ATP depletion experiments confirm ATP-independent chaperone activity of TXNL1

  • Kinetic measurements of TXNL1-substrate interactions help determine binding mechanisms

  • Domain-specific mutants can help attribute specific functions to different regions of TXNL1

Research has demonstrated that TXNL1's Km with TXNRD1 is at least one order of magnitude higher than that of Trx1, explaining its lower catalytic efficacy in redox reactions despite similar substrate specificity . This highlights the importance of quantitative kinetic measurements when characterizing TXNL1's functional properties.

How can TXNL1 antibodies be used to investigate the protein's role in proteasome function?

TXNL1 antibodies are valuable tools for exploring the interaction between TXNL1 and the proteasome complex:

• Co-immunoprecipitation approaches:

  • Use TXNL1 antibodies to pull down TXNL1 and associated proteasome components

  • Reciprocal IP with antibodies against proteasome subunits (especially Rpn11) to capture TXNL1

  • Western blot analysis of immunoprecipitates can identify specific proteasome components that interact with TXNL1

• Proximity ligation assays (PLA):

  • Combine TXNL1 antibodies with antibodies against 19S, 20S, or 26S proteasome components

  • Visualize in situ interactions between TXNL1 and proteasome components with subcellular resolution

  • Quantify interaction signals under different cellular stress conditions

• Immunofluorescence co-localization:

  • Use dual immunostaining with TXNL1 antibodies and proteasome markers

  • Analyze co-localization under normal and stress conditions (oxidative stress, glucose deprivation)

  • Examine dynamics using live-cell imaging approaches

• Functional assessment methodologies:

  • Monitor proteasome activity after TXNL1 knockdown/overexpression

  • Use TXNL1 antibodies to track changes in TXNL1-proteasome association under stress conditions

  • Compare wild-type vs. redox-inactive TXNL1 mutants to determine if redox activity influences proteasome binding

Research has established that TXNL1 associates with both the 19S and 20S particles, as well as the mature 26S proteasome . These interactions suggest TXNL1 may act as a molecular bridge between cellular redox status and protein degradation pathways, highlighting a potential regulatory mechanism for proteasome function in response to oxidative stress.

What approaches can be used to study TXNL1 in response to oxidative stress and its role as a redox sensor?

Investigating TXNL1's function as a redox sensor requires specialized experimental strategies:

• Redox state analysis:

  • Redox Western blotting: Use non-reducing conditions to preserve disulfide bonds, followed by detection with TXNL1 antibodies

  • Alkylation assays: Block free thiols before cell lysis, then analyze TXNL1's oxidation state

  • Mass spectrometry approaches to identify specific oxidative modifications of TXNL1 cysteines

• Functional readouts of TXNL1-mediated responses:

  • Endocytosis assays: Monitor GDI:Rab5-mediated endocytic response as an indicator of TXNL1's redox sensing function

  • Signaling pathway activation: Analyze downstream effectors modulated by TXNL1 under oxidative stress

  • Proteomic analysis of TXNL1 interactome under oxidative conditions using TXNL1 antibody pull-downs followed by mass spectrometry

• Cellular response monitoring:

  • Knockdown/overexpression studies: Assess how TXNL1 levels affect cellular responses to various oxidative stressors

  • Cysteine mutant comparisons: Use TXNL1 active site mutants to determine which cysteines are critical for its redox sensing function

  • Live-cell imaging with redox-sensitive probes: Correlate TXNL1 activity with real-time cellular redox changes

• Physiological stress models:

  • Glucose deprivation: TXNL1 has been shown to protect cells against glucose deprivation but not H₂O₂ treatment

  • Auranofin treatment: Investigate why TXNL1 is rapidly downregulated in cancer cells treated with auranofin

  • Disease models associated with redox imbalance (cancer, neurodegenerative disorders, cardiovascular disease)

These approaches can help elucidate how TXNL1 converts redox changes into specific cellular responses, particularly through its role in coupling oxidative stress to endocytosis via GDI:Rab5-mediated pathways .

How can I investigate the relationship between TXNL1 and thioredoxin reductase (TXNRD1) in experimental systems?

Studying the functional relationship between TXNL1 and TXNRD1 requires specialized biochemical and cellular approaches:

• Enzyme kinetics analysis:

  • Determine Km and Vmax values for TXNRD1-mediated reduction of TXNL1 compared to TXN

  • Research has shown that TXNRD1 has at least one order of magnitude higher Km for TXNL1 compared to Trx1, explaining its lower catalytic efficacy

  • Use purified recombinant proteins to generate detailed enzyme kinetics profiles

• Interaction studies:

  • Co-immunoprecipitation using TXNL1 antibodies to pull down TXNRD1

  • Surface plasmon resonance (SPR) to measure binding affinities and kinetics

  • Microscale thermophoresis to determine interaction parameters under different redox conditions

• Cellular manipulation approaches:

  • TXNRD1 inhibition: Use auranofin or other specific inhibitors to block TXNRD1 and monitor effects on TXNL1 function

  • Gene silencing: Knockdown TXNRD1 to assess TXNL1-dependent functions

  • Domain mapping: Identify specific regions of TXNL1 required for interaction with TXNRD1

• Functional consequence analysis:

  • Compare TXNL1's disulfide reduction activity in the presence/absence of functional TXNRD1

  • Evaluate whether TXNL1's chaperone activity persists independently of TXNRD1 function

  • Determine cell viability and stress responses when the TXNL1-TXNRD1 axis is disrupted

• Redox proteomics approaches:

  • OxICAT or ICDID methodologies to measure redox changes in TXNL1 substrates

  • Redox western blotting to monitor TXNL1 oxidation state when TXNRD1 is inhibited

  • Global proteomic profiling to identify pathways affected by disruption of the TXNL1-TXNRD1 system

Understanding this relationship is particularly important given that TXNL1 is rapidly downregulated in cancer cells treated with auranofin, an FDA-approved TXNRD1 inhibitor currently being evaluated for repurposing in cancer treatment .

What are common challenges when using TXNL1 antibodies and how can they be addressed?

Researchers working with TXNL1 antibodies may encounter several technical challenges:

• Non-specific binding and background:

  • Problem: High background staining in immunohistochemistry or multiple bands in Western blot

  • Solution: Increase blocking time/concentration (5-10% normal serum or BSA), optimize antibody dilution (start with 1:500 for WB and 1:100 for IHC), and include 0.1-0.3% Triton X-100 in wash buffers

  • Validation: Include appropriate negative controls (isotype controls, TXNL1 knockdown samples)

• Inconsistent detection:

  • Problem: Variable signal intensity between experiments

  • Solution: Standardize lysate preparation (consistent cell density, lysis conditions), use loading controls (β-actin, GAPDH), and prepare fresh antibody dilutions for each experiment

  • Refinement: Consider using K-562 or HL-60 cells as positive controls for consistent TXNL1 expression

• Detection of TXNL1 in different redox states:

  • Problem: Difficulty distinguishing oxidized vs. reduced forms

  • Solution: Implement non-reducing SDS-PAGE conditions when studying redox states, use alkylating agents to trap the native redox state, and compare with redox-inactive TXNL1 mutants

  • Analysis: Run parallel reduced and non-reduced samples to visualize redox-dependent mobility shifts

• Epitope masking in native complexes:

  • Problem: Poor detection of TXNL1 when complexed with proteasome or other partners

  • Solution: Try multiple antibodies targeting different epitopes, optimize antigen retrieval conditions (TE buffer pH 9.0 vs. citrate buffer pH 6.0) , and consider native vs. denaturing conditions

  • Application adjustment: For co-IP studies, use mild detergents that preserve protein-protein interactions

• Cross-reactivity with other thioredoxin family members:

  • Problem: Antibody recognizing related proteins like TXN due to homology in the N-terminal domain

  • Solution: Validate specificity using recombinant proteins, perform pre-absorption tests, and confirm results with orthogonal methods

  • Control strategy: Include TXN-expressing vs. TXNL1-expressing samples to confirm specificity

Each antibody may have unique characteristics requiring optimization for specific applications and experimental systems.

How can I differentiate between TXNL1's redox activity and chaperone functions in experimental settings?

Separating TXNL1's dual functions requires strategic experimental design:

• Protein engineering approach:

  • Generate site-directed mutants of the TXNL1 active site cysteines (Cys-to-Ser substitutions)

  • Characterize these variants in parallel redox and chaperone assays

  • Research has demonstrated that TXNL1's chaperone activities remain intact even with Cys-to-Ser mutations that abolish redox activity

• Functional separation assays:

  • Insulin reduction assay with turbidity monitoring: Wild-type TXNL1 will reduce insulin disulfides while preventing precipitation, whereas redox-inactive mutants will only prevent precipitation

  • Heat-induced protein aggregation assays: Both wild-type and redox-inactive TXNL1 variants protect cell lysate proteins from aggregation during heating, confirming redox-independent chaperone activity

  • ATP depletion experiments: TXNL1's chaperone function persists without ATP, distinguishing it from ATP-dependent chaperones

• Biochemical separation strategies:

  • TXNRD1/NADPH dependence: Redox activity requires the TXNRD1/NADPH system while chaperone function does not

  • Substrate specificity analysis: Compare disulfide-containing vs. non-disulfide substrates

  • Domain-specific antibodies or truncation mutants to attribute functions to specific regions of TXNL1

• Cellular approaches:

  • Inducible expression of wild-type vs. redox-inactive TXNL1 followed by stress challenges

  • Proteomic comparison of binding partners for wild-type vs. redox-inactive TXNL1

  • Cell-based assays for protein aggregation vs. redox homeostasis

These approaches allow researchers to dissect which cellular functions of TXNL1 depend on its redox activity versus its chaperone properties, providing insight into how this dual-function protein contributes to cellular proteostasis and redox homeostasis.

What specialized techniques can reveal TXNL1's protein-protein interactions in cellular contexts?

Uncovering TXNL1's interaction network requires advanced methodologies:

• Affinity purification coupled with mass spectrometry (AP-MS):

  • Use TXNL1 antibodies for immunoprecipitation followed by MS identification of interactors

  • Employ stable isotope labeling (SILAC) to quantitatively compare interaction partners under different conditions

  • Consider comparing wild-type TXNL1 vs. active site mutants to identify redox-dependent interactions

  • Research has shown that TXNL1 binds significantly more proteins in HEK293 cells compared to Trx1 (1655 vs. 379, respectively)

• Proximity-dependent labeling approaches:

  • BioID or TurboID: Express TXNL1 fused to a biotin ligase to label proximal proteins

  • APEX2: TXNL1-APEX2 fusions can biotinylate nearby proteins upon H₂O₂ treatment

  • These methods capture transient and weak interactions in the native cellular environment

• High-resolution microscopy techniques:

  • Förster resonance energy transfer (FRET) to detect direct protein-protein interactions

  • Fluorescence lifetime imaging microscopy (FLIM) for more quantitative interaction analysis

  • Super-resolution microscopy to visualize TXNL1 co-localization with proteasome components or other partners

• Crosslinking mass spectrometry (XL-MS):

  • Use chemical crosslinkers to stabilize TXNL1 protein complexes

  • MS analysis identifies not only interacting partners but also specific contact points

  • Particularly valuable for studying TXNL1's association with large complexes like the proteasome

• Interactome mapping under varying conditions:

  • Compare TXNL1 interaction networks under normal vs. oxidative stress conditions

  • Analyze proteome-wide effects of glucose deprivation on TXNL1 interactions

  • Study how auranofin treatment affects TXNL1's association with TrxR1 and other partners

These techniques can help elucidate how TXNL1's interaction network changes in response to cellular stressors, providing insight into its role in stress adaptation and proteostasis.

How does TXNL1 expression and function change in pathological conditions?

TXNL1's involvement in various pathologies is an emerging area of research:

• Cancer biology:

  • TXNL1 is uniquely and rapidly downregulated in cancer cells treated with auranofin, suggesting potential therapeutic relevance

  • Expression pattern analysis using TXNL1 antibodies can identify cancer-specific alterations

  • Research focus areas include correlating TXNL1 levels with cancer progression, treatment response, and patient outcomes

• Neurodegenerative disorders:

  • TXNL1's dual redox and chaperone functions suggest potential roles in protein misfolding diseases

  • Investigate whether TXNL1 dysfunction contributes to aggregation of disease-specific proteins

  • Compare TXNL1 expression and oxidation state in affected vs. unaffected brain regions

• Cardiovascular disease:

  • Oxidative stress is a key factor in cardiovascular pathologies

  • TXNL1 antibodies can help track expression changes in response to ischemia-reperfusion injury

  • Potential protective roles through either redox activity or chaperone function merit investigation

• Methodological approaches:

  • Tissue microarray analysis using TXNL1 antibodies to screen multiple disease samples

  • Single-cell proteomics to identify cell type-specific alterations in TXNL1 expression

  • Animal models with TXNL1 knockout/knockdown to assess disease susceptibility

  • Omics integration to correlate TXNL1 status with global cellular changes

• Translational potential:

  • Development of TXNL1-targeted therapies based on its protective functions

  • Use of TXNL1 as a biomarker for disease progression or treatment response

  • Therapeutic exploitation of the TXNL1-proteasome relationship in diseases with proteasome dysfunction

Understanding TXNL1's roles in pathological conditions may reveal new therapeutic targets and diagnostic approaches for diseases characterized by redox imbalance and protein homeostasis disruption.

What are the most promising research directions for understanding TXNL1's cellular functions?

Several cutting-edge research areas are particularly promising for advancing our understanding of TXNL1 biology:

• Systems biology of TXNL1 networks:

  • Integration of interactome, redoxome, and proteome data to build comprehensive models of TXNL1 function

  • Network analysis to identify central nodes in TXNL1-regulated pathways

  • Machine learning approaches to predict cellular contexts where TXNL1 functions are critical

• Structure-function relationships:

  • High-resolution structural studies of TXNL1 in different redox states

  • Conformational dynamics of TXNL1 during its dual functions of redox activity and chaperone function

  • Structure-guided development of tools to selectively modulate specific TXNL1 functions

• Cellular stress response integration:

  • TXNL1's role in coordinating proteasome function with redox homeostasis

  • Investigation of TXNL1 as a potential integrated sensor coupling multiple stress response pathways

  • Real-time imaging of TXNL1 dynamics during cellular stress using fluorescent fusion proteins

• Developmental and tissue-specific functions:

  • Spatio-temporal expression patterns of TXNL1 during development

  • Tissue-specific TXNL1 functions using conditional knockout models

  • Cell type-specific interactions and functions using single-cell approaches

• Translational research opportunities:

  • TXNL1 as a potential drug target for diseases with redox imbalance or protein aggregation

  • Development of small molecules to selectively modulate TXNL1's redox or chaperone functions

  • Biomarker potential for monitoring cellular stress states in various pathologies

The discovery that TXNL1 has dual functions as both a redox enzyme and a chaperone opens new avenues for research into how cells integrate these protective mechanisms in their stress response networks.

How can the latest technological advances be applied to study TXNL1 in complex biological systems?

Cutting-edge technologies offer unprecedented opportunities for TXNL1 research:

• CRISPR-based functional genomics:

  • Generate precise TXNL1 knock-in models with domain-specific mutations

  • CRISPRi/CRISPRa systems for conditional modulation of TXNL1 expression

  • CRISPR screens to identify synthetic lethal interactions with TXNL1 deficiency

• Advanced imaging technologies:

  • Live-cell redox imaging coupled with TXNL1-fluorescent protein fusions

  • FRET-based sensors to monitor TXNL1 redox state in real-time

  • Super-resolution microscopy to visualize TXNL1-proteasome interactions at nanoscale resolution

• Single-cell approaches:

  • Single-cell proteomics to map TXNL1 expression heterogeneity

  • Single-cell transcriptomics combined with TXNL1 protein analysis

  • Spatial transcriptomics to map TXNL1 expression patterns in complex tissues

• In vivo models and methods:

  • Tissue-specific and inducible TXNL1 knockout models

  • Patient-derived organoids to study TXNL1 function in disease contexts

  • Intravital microscopy to monitor TXNL1 dynamics in living organisms

• Computational and AI approaches:

  • Machine learning prediction of TXNL1 substrates and interaction partners

  • Molecular dynamics simulations of TXNL1's conformational changes during chaperone/redox activities

  • Systems biology integration of multi-omics data to model TXNL1 functions

These technological advances will enable researchers to move beyond reductionist approaches and understand TXNL1's functions in the context of intact biological systems, potentially revealing emergent properties and previously unrecognized roles in cellular homeostasis and disease pathogenesis.